Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC
Status:
NOT_YET_RECRUITING
Trial end date:
2027-08-30
Target enrollment:
Participant gender:
Summary
To explore the application of Sacituzumab Tirumotecan in neoadjuvant treatment of early-stage TNBC, a multicenter, Phase II clinical study of Sacituzumab Tirumotecan in neoadjuvant treatment of early-stage TNBC is proposed. The study aims to evaluate the efficacy and safety of Sacituzumab Tirumotecan and to provide a new treatment option for neoadjuvant treatment of early-stage TNBC.